Altis Labs
- Company typePrivate
- Founded2019
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Altis Labs firmographics
Firmographics- Name
- Altis Labs
- Legal name
- Altis Labs, Inc.
- Website
- https://altislabs.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Altis Labs industry classification
Industry- Product category
- AI-Powered Clinical Trial Imaging Analytics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where Altis Labs is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Altis Labs business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Biopharma Software Licensing: B2B SaaS model providing biopharma sponsors access to AI models via the Nota platform for analyzing clinical trial imaging data. Revenue likely generated through platform licensing and analysis fees per trial or per patient.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Altis Labs product offering
Product offeringCore offering
Altis Labs develops AI-powered imaging analysis software for biopharma clinical trials. Its Nota platform processes CT scans through deep learning models (IPRO) to predict patient outcomes, quantify treatment effects earlier than traditional RECIST measurements, and generate external control arms via Real-World Digital Twins. The platform serves top biopharma sponsors conducting oncology trials, providing patient stratification, treatment effect quantification, and regulatory-grade endpoint analysis.
Product overview
Altis Labs offers the Nota platform, a cloud-based AI-powered imaging biomarker platform that hosts proprietary deep learning models for clinical trial imaging analysis. The core product is IPRO (Imaging-based Prognostication), which includes IPRO-α for baseline predictions and IPRO-Δ for longitudinal change assessment. IPRO processes CT scans through 3D convolutional neural networks to generate prognostic scores and 5,000+ Spatial Imaging Biomarkers per scan. The platform also includes Real-World Digital Twins and External Control Arm products that leverage multimodal real-world data to create AI-matched control groups for clinical trials. Biopharma sponsors use Nota to analyze imaging data from Phase 1-4 clinical trials to more accurately stratify patients and quantify treatment effect earlier in development.
Differentiator
Problem solved
Functional benefit
Brands
- Nota: AI-powered imaging biomarker platform that enables biopharma sponsors to manage and automatically analyze imaging data from clinical trials using prognostic AI models. Nota hosts proprietary prognostic models including IPRO for automated patient outcome predictions.
- IPRO
- Real-World Digital Twins (rwDTs)
Products and services
- Nota Platform Web-based platform for managing and automatically analyzing clinical trial imaging data with AI models. Nota enables users to upload de-identified DICOM data, automatically quality control and index meta- and pixel data, generate IPRO scores and Spatial Imaging Biomarkers, and query data in a secure, access-controlled environment. Designed for biopharma sponsors and clinical research institutions conducting oncology trials.
- IPRO (Imaging-based Prognostication) Fully-automated deep learning system that predicts patient outcomes from CT scans. IPRO uses 3D convolutional neural networks trained on longitudinal real-world imaging data to generate prognostic scores and thousands of explainable Spatial Imaging Biomarkers (SIBs) per scan, enabling patient stratification and treatment effect quantification beyond traditional tumor measurements. Serves biopharma sponsors conducting oncology clinical trials.
- Real-World Digital Twins (rwDTs) AI-matched digital twins generated from real-world patient data to create External Control Arms (ECAs) for clinical trials. Identifies matching historical patients using baseline imaging characteristics and clinical data to emulate control arm outcomes and treatment effects. Designed for biopharma sponsors running single-arm oncology trials.
- External Control Arm (ECA) Product offering enabling biopharma sponsors to generate multimodal external controls using clinical trial imaging data and Altis' real-world imaging data with associated survival outcomes. Used for benchmarking efficacy signal in single-arm trials, augmenting control arms in RCTs, and informing reimbursement strategy.
Quantifiable outcome
- IPRO-Δ had greater association with OS (HR=1.72, 95% CI: 1.38-2.15) than ΔSLD (HR=1.14) in Bayer's Phase 3 NExUS trial
- +2 more outcomes
Companies that use Altis Labs
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Altis Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Altis Labs partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, major and supporting.
- Johnson & Johnson Innovative MedicinecoreCollaboration agreement to leverage AI models for supporting clinical trials, evaluating novel outcome measures to potentially accelerate trial timelines and reduce costs.
- University Health Network (UHN)coreMulti-year partnership focused on lung, breast, colorectal, prostate, and liver cancer. Combines AI research with UHN's clinical expertise to accelerate cancer research.
- Hamilton Health SciencesmajorResearch collaboration to develop and evaluate prognostic AI models for breast cancer. Led by Dr. Jeremy Petch at CREATE center.
- AstraZenecacoreEarly access to AI-driven digital twins for four clinical trials. AstraZeneca independently evaluated IPRO in MYSTIC Phase 3 trial, demonstrating IPRO-Δ enhances survival prediction compared to RECIST.
- Bayer PharmaceuticalscoreEarly access to AI models via Nota for four clinical trials. Bayer evaluated IPRO in NExUS Phase 3 trial, demonstrating superior prognostic association compared to SLD.
- Trillium Health PartnersmajorPart of international coalition for digital twins in clinical trials. Dr. Benjamin Fine leads initiative via AI Deployment and Evaluation Lab.
- University of CalgarymajorAcademic partner in digital twins initiative. Dr. Omar Khan leads project, presenting results at ELCC 2025 and ESMO.
- BC CancermajorCoalition member in pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning.
- Sunnybrook Research InstitutemajorCoalition member in pan-Canadian initiative. Host of INOVAIT network headquarters.
- SapienSecuresupportingCanadian data company providing NLP tools for digital twins initiative to facilitate data processing.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Altis Labs competitors and assessment
Company assessmentDirect peers
- Median Technologies: Imaging AI and imaging CRO focused on oncology clinical trials, offering imaging biomarkers, lesion management, and AI-driven analysis to biopharma sponsors. Directly comparable as an imaging AI vendor serving top pharma in oncology trials.
- Artera (formerly ArteraAI): AI-based multimodal prognostic and predictive biomarker company, notably in prostate cancer, building evidence-based diagnostic tests that help biopharma stratify patients and improve trial outcomes. Closely analogous as an AI prognostic biomarker company targeting biopharma.
- ConcertAI: AI-enabled real-world evidence and clinical trial solutions company in oncology, providing biopharma with data, analytics, and external control arms. Comparable in addressing trial design, ECA, and oncology-focused RWE for top sponsors.
- Owkin: AI-for-drug-discovery and clinical research company that builds predictive models on multimodal patient data to support biopharma trial design and target identification. Comparable as a biopharma-focused AI platform leveraging real-world data.
- Paige.AI: AI pathology company developing clinical-grade diagnostic and biomarker products for oncology, with biopharma partnerships around trial endpoints and CDx. Comparable as an AI-driven diagnostic/biomarker company serving oncology drug development.
- PathAI: AI-powered pathology platform offering biomarker discovery, diagnostics, and biopharma research partnerships, including partnerships with pharma on clinical trial endpoints. Comparable as a pathology/imaging AI vendor for oncology trials.
Broad incumbents
- Flatiron Health: Real-world oncology data and analytics platform acquired by Roche for $1.9B; provides RWE, EHR-derived datasets, and clinical research tools to biopharma. Adjacent incumbent in AI/real-world data for oncology trials.
- Tempus: AI-enabled precision medicine company with multimodal data (imaging, molecular, clinical) and biopharma services spanning trial design, biomarker discovery, and CDx. Comparable as a large multimodal AI/data platform for biopharma R&D.
- Medidata (Dassault Systèmes): Market-leading clinical trial technology platform offering EDC, eCOA, imaging, and AI-driven analytics to biopharma. Comparable incumbent in clinical trial imaging/analytics, representing both a potential channel and competitor.
- Verily (Alphabet): Life sciences and clinical research technology platform from Alphabet, providing real-world data, decentralized trials, and biomarker solutions to biopharma. Comparable as a well-capitalized technology provider in clinical research and precision health.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Altis Labs social profiles
Digital presenceAltis Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altis Labs leadership team
Management profileNumber of profiles
Profiles15 records
Altis Labs funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altis Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altis Labs
What does Altis Labs do?
Altis Labs develops AI-powered imaging analysis software for biopharma clinical trials. Its Nota platform processes CT scans through deep learning models (IPRO) to predict patient outcomes, quantify treatment effects earlier than traditional RECIST measurements, and generate external control arms via Real-World Digital Twins. The platform serves top biopharma sponsors conducting oncology trials, providing patient stratification, treatment effect quantification, and regulatory-grade endpoint analysis.
Is Altis Labs a public or private company?
Altis Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Altis Labs founded?
Altis Labs was founded in 2019. It employs 11 to 50 people.
Where is Altis Labs based?
Altis Labs is headquartered in Toronto, Canada, in the North America region.
How does Altis Labs make money?
One revenue line is on record: biopharma Software Licensing.
Who are Altis Labs's main competitors?
Direct peers on record are Median Technologies, Artera (formerly ArteraAI), ConcertAI, Owkin, Paige.AI and PathAI. Broad incumbents are Flatiron Health, Tempus, Medidata (Dassault Systèmes) and Verily (Alphabet).
Does Altis Labs have an API?
No public API is recorded for Altis Labs.
What industry is Altis Labs in?
Altis Labs's product category is AI-Powered Clinical Trial Imaging Analytics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 541714 and its SIC code is 8731.